Author(s)

Zongyou Jiang

Corresponding Author

Zongyou Jiang

ABSTRACT

Tumors that are malignant are one of the most serious threats to human health today. As per the 2018 Global Cancer Statistics, published in the American Cancer Society's official journal, roughly 18.1 million additional cancer cases and 9.6 million cancer deaths will occur worldwide in 2018 [1]. Although surgery, radiation, chemotherapy, and targeted therapy are the most effective therapies for malignancies, each of these treatments has limitations. However, each of these treatments has distinct limits, and the overall therapy impact is poor, as is the patient's long-term survival percentage. Tumor immunotherapy is a relatively new form of tumor treatment that has made tremendous development in recent years. It is a way for controlling and eliminating tumors by beginning and sustaining the tumor-immune cycle and reestablishing the body's normal anti-tumor immune response. Neoantigens have arisen as a new study avenue in tumor immunotherapy in recent years, and current research findings indicate that neoantigens are particularly useful in immune checkpoint inhibitor therapy, TIL therapy, and the generation of therapeutic tumor vaccines. We discuss the advancement of personalized vaccines based on neoantigens in this article.

KEYWORDS

Tumor, neoantigen vaccine, cancer vaccin, cancer immunotherapy